Shares of Avacta Group Plc (LON:AVCT – Get Free Report) passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 60.97 and traded as high as GBX 63. Avacta Group shares last traded at GBX 61, with a volume of 3,769,863 shares changing hands.
Wall Street Analyst Weigh In
Separately, Peel Hunt reaffirmed a “buy” rating and issued a GBX 99 target price on shares of Avacta Group in a report on Monday, October 13th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of GBX 99.
View Our Latest Research Report on Avacta Group
Avacta Group Price Performance
About Avacta Group
Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.
Our proprietary pre|CISIONĀ® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).
Featured Stories
- Five stocks we like better than Avacta Group
- The day the gold market broke
- Buy this Gold Stock Before May 2026
- Forget AI, This Will Be the Next Big Tech Breakthrough
- Trump Planning to Use Public Law 63-43: Prepare Now
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.
